Dementia Discovery Fund — 2022 Investments
1 investments dated 2022 · listed companies and verified rows first · show all
Amphistaamphista.comin𝕏Dec 2022
Amphista Therapeutics develops next-generation targeted protein degradation (TPD) medicines using its proprietary Targeted Glue technology, which is engineered to selectively trigger the destruction of disease-causing proteins.
BiotechCambridge, GB
Louise Modis(Chief Executive Officer)inMartin Pass(Chief Development Officer)inGiles Brown(Executive VP Drug Discovery)in
Co-investorsAdvent Life SciencesNovartis Venture FundSV Health InvestorsEuropean Investment FundForbionGilde Healthcare+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.